AstraZeneca Arimidex
Executive Summary
Anastrozole tablets receive FDA approval Sept. 1 for first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. AstraZeneca has committed to submit annual safety and survival updates for its pivotal studies until 75% of patients are deceased. Arimidex was previously approved for use following patient failure on AstraZeneca's Nolvadex. The first-line indication will allow AstraZeneca to complement Nolvadex, which saw a sales decline of 5% in the first half
You may also be interested in...
Femara First-Line Breast Cancer Label Includes Tamoxifen Superiority Claim
Novartis' Femara (letrozole) first-line breast cancer approval Jan. 10 is based on superiority over tamoxifen (AstraZeneca's Nolvadex and Barr's generic).
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011